Cerebral venous thrombosis: a changing landscape

Vimala Colaco, Harsha Sundaramurthy, Shasthara Paneyala, Nemichandra S. C.


Cerebral venous thrombosis (CVT) is an uncommon cause of stroke and is mainly a disease of the young. The aims of the study were to summarize the change in the clinical profile of CVT and provide an update regarding the current management of the same. A literature search was conducted using Pubmed and Google scholar using the desired terms. Studies were analysed and review was formulated. The median age of CVT in most studies was 32 years. There has been a shift from female pre-ponderence to equal gender predilection. Several studies are confirming the efficacy of D-dimer as a diagnostic marker of CVT. Newer oral anticoagulants have been found to be as efficient as warfarin. There have been several cases of CVT reported in association with COVID-19. This review confirmed the traditional understanding of age and risk factors of CVT. It also noted a change from the female pre-ponderence. NOACS are emerging as the preferred drug for the long-term management of CVT.


Cerebral venous thrombosis, Clinical profile, Biomarkers, NOACS

Full Text:



Ulivi L, Squitieri M, Cohen H, Cowley P, Werring DJ. Cerebral venous thrombosis: a practical guide. Pract Neurol. 2020;20(5):356-67.

Saposnik G, Barinagarrementeria F, Brown RD, Bushnell CD, Cucchiara B, Cushman M, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(4):1158-92.

Ferro JM, Canhao P, Stam J, Bousser MG, Barinagarrementeria F, ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35(3):664-70.

Ghosh R, Roy D, Mandal A, Pal SK, Chandra Swaika B, Naga D, et al. Cerebral venous thrombosis in COVID-19. Diabetes Metab Syndr. 2021;15(3):1039-45.

Hughes C, Nichols T, Pike M, Subbe C, Elghenzai S. Cerebral Venous Sinus Thrombosis as a Presentation of COVID-19. Eur J Case Rep Intern Med. 2020;7(5):001691.

Ramrakhiani N, Sharma DK, Dubey R, Gupta P, Sharma A, Sharma KK. Clinical Profile, Risk Factors and Outcomes in Patients with Cerebral Venous Sinus Thrombosis: A Study from Western India. J Assoc Physicians India. 2019;67(9):49-53.

Pathak A, Nath CR, Kumar SV, Shukla U, Joshi D, Nath MV. Clinico-radiological profile of CVT patients and its correlation with D-dimer. J Clin Neurosci. 2020;78:139-42.

Narayan D, Kaul S, Ravishankar K, Suryaprabha T, Bandaru VC, Mridula KR, et al. Risk factors, clinical profile, and long-term outcome of 428 patients of cerebral sinus venous thrombosis: insights from Nizam's Institute Venous Stroke Registry, Hyderabad (India). Neurol India. 2012;60(2):154-9.

Pai N, Ghosh K, Shetty S. Hereditary thrombophilia in cerebral venous thrombosis: a study from India. Blood Coagul Fibrinolysis. 2013;24(5):540-3.

Cumurciuc R, Crassard I, Sarov M, Valade D, Bousser MG. Headache as the only neurological sign of cerebral venous thrombosis: a series of 17 cases. J Neurol Neurosurg Psychiatry. 2005;76(8):1084-7.

Idiculla PS, Gurala D, Palanisamy M, Vijayakumar R, Dhandapani S, Nagarajan E. Cerebral Venous Thrombosis: A Comprehensive Review. Eur Neurol. 2020;83(4):369-79.

Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352(17):1791-8.

Masuhr F, Busch M, Amberger N, Ortwein H, Weih M, Neumann K, et al. Risk and predictors of early epileptic seizures in acute cerebralvenous and sinus thrombosis. Eur J Neurol. 2006;13(8):852-6.

Ferro JM, Canhao P, Sousa D. Cerebral venous thrombosis. Presse Med. 2016;45(12):429-50.

Thorell SE, Jones AR, Punter M, Hurford R, Thachil J. Cerebral venous thrombosis-a primer for the haematologist. Blood Rev. 2015;29(1):45-50.

Palomo MS, EJA, Ayala SA, Moya JM. Transient ischemic attack: the only presenting syndrome of dural sinus thrombosis. Neurologia. 2006;21(3):155-8.

Ferro JM, Canhao P, Bousser MG, Stam J, Barinagarrementeria F, ISCVT Investigators. Cerebral vein and dural sinus thrombosis in elderly patients. Stroke. 2005;36(9):1927-32.

Ferro JM, Canhao P, Bousser MG, Stam J, Barinagarrementeria F, ISCVT Investigators. Cerebral vein and dural sinus thrombosis in women patients. Stroke. 2009;40(7):2356-61.

Saroja AO, Tapsi C, Naik KR. Cerebral venous thrombosis in women from Indian subcontinent. J Sci Soc. 2017;44:20-5.

Barboza MA, Chiquete E, Arauz A, Merlos BM, Compeán A, Barinagarrementería F, et al. A Practical Score for Prediction of Outcome After Cerebral Venous Thrombosis. Front Neurol. 2018;9:882.

Dmytriw AA, Song JSA, Yu E, Poon CS. Cerebral venous thrombosis: state of the art diagnosis and management. Neuroradiology. 2018;60(7):669-85.

Kothare SV, Ebb DH, Rosenberger PB, Buonanno F, Schaefer PW, Krishnamoorthy KS. Acute confusion and mutism as a presentation of thalamic strokes secondary to deep cerebral venous thrombosis. J Child Neurol. 1998;13(6):300-3.

Canhao P, Ferro JM, Lindgren AG, Bousser MG, Stam J, Barinagarrementeria F; ISCVT Investigators. Causes and predictors of death in cerebral venous thrombosis. Stroke. 2005;36(8):1720-5.

Li H, Yao M, Liao S, Chen J, Yu J. Comparison of Novel Oral Anticoagulants and Vitamin K Antagonists in Patients With Cerebral Venous Sinus Thrombosis on Efficacy and Safety: A Systematic Review. Front Neurol. 2020;11:597623.

Ferro JM, Coutinho JM, Dentali F, Kobayashi A, Alasheev A, Canhao P, Karpov D, et al. Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial. JAMA Neurol. 2019;76(12):1457-65.

Nwajei F, Anand P, Abdalkader M, Andreu AVC, Aparicio HJ, Behbahani S, et al. Cerebral Venous Sinus Thromboses in Patients with SARS-CoV-2 Infection: Three Cases and a Review of the Literature. J Stroke Cerebrovasc Dis. 2020;29(12):105412.

Ciccone A. SARS-CoV-2 vaccine-induced cerebral venous thrombosis. Eur J Intern Med. 2021;89:19-21.